| Project/Area Number |
09670141
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General medical chemistry
|
|---|
| Research Institution | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE |
|---|
Principal Investigator |
KAWAKITA Masao Tokyo Metropolitan Institute of Medical Science Department of Physiological Chemistry, Investigator, 医化学研究部門, 研究員 (00012740)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIRAMATSU Kyoko Tokyo Metropolitan Institute of Medical Science Department of Physiological Chem, 医化学研究部門, 研究員 (80181189)
HOSHINO Masato Tokyo Metropolitan Institute of Medical Science Department of Physiological Chem, 生命情報研究部門, 研究員 (40212196)
MIKI Toshiaki Tokyo Metropolitan Institute of Medical Science Department of Physiological Chem, 医化学研究部門, 研究員 (10239204)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1998: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | Polyamine / Diacetylspermine / Diacetylspermicine / ELISA / Anti-polyamine antibody / Tumor marker |
|---|
| Research Abstract |
Antibodies specific toN^1, N^8-diacetylspermidine (DiAcSpd) AndN^1, N^<12>-diacetylspermine (DiAcSpm) were reised in rabbits and were affinity-pufified, using affinity-1 igands mimicking DiAcSpm and DiAcSpd. Cross-reactivity of Ant i-DiAcSpm antibody with N^1-acetylspermidine was only about 0.03%. A competitive ELISA system for the determination of urinary diAcSpm was developed, using this highly DiAcSpm-selective antibody. The ELISA system allowed accurate determination of DiAcSpm concentrations as low as 10-20 nM and the values obtained by this procedure coinceded very well with those determined by HPLC.Determination of the amount of DiAcSpm in the urine of patients with urogenital malignancies revealed several points as follows : (1) The DiAcSpm levels were high inmost testicular and renal cancer cases except for those at very early stages. On the other hand, in cases of bladder cancer, DiAcSpm values frequently stayed within the normal range (mean for healthy persons + 2S.D.) even with patients at advanced stages. (2) The DiAcSpm levels after treatments of prostate cancer were well correlated with the patients' prognosis. In cases where DiAcSpm was low and stationary after treatments, the prognosis of patients turned out to be favorable even though the PSA value remained high in several cases. In contrast, when DiAcSpm remained elevated after a treatment, prognosis of the patient was poor, even if the treatment had been apparently effective and had temporarily led to partial remission. These results strongly suggest that DiAcSpm serves as a good indicator of the prognosis of prostate cancer, and that it works much better than PSA in this respect.
|
